Publication:
APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome.

dc.contributor.authorFallaize, Rosalind
dc.contributor.authorCarvalho-Wells, Andrew L
dc.contributor.authorTierney, Audrey C
dc.contributor.authorMarin, Carmen
dc.contributor.authorKieć-Wilk, Beata
dc.contributor.authorDembińska-Kieć, Aldona
dc.contributor.authorDrevon, Christian A
dc.contributor.authorDeFoort, Catherine
dc.contributor.authorLopez-Miranda, Jose
dc.contributor.authorRiserus, Ulf
dc.contributor.authorSaris, Wim H
dc.contributor.authorBlaak, Ellen E
dc.contributor.authorRoche, Helen M
dc.contributor.authorLovegrove, Julie A
dc.contributor.funderEuropean Commission Framework Programme 6
dc.date.accessioned2023-01-25T09:49:26Z
dc.date.available2023-01-25T09:49:26Z
dc.date.issued2017-06-05
dc.description.abstractMetabolic markers associated with the Metabolic Syndrome (MetS) may be affected by interactions between the APOE genotype and plasma fatty acids (FA). In this study, we explored FA-gene interactions between the missense APOE polymorphisms and FA status on metabolic markers in MetS. Plasma FA, blood pressure, insulin sensitivity and lipid concentrations were determined at baseline and following a 12-week randomized, controlled, parallel, dietary FA intervention in 442 adults with MetS (LIPGENE study). FA-APOE gene interactions at baseline and following change in plasma FA were assessed using adjusted general linear models. At baseline E4 carriers had higher plasma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B) compared with E2 carriers; and higher TC, LDL-C and apo B compared with E3/E3. Whilst elevated plasma n-3 polyunsaturated FA (PUFA) was associated with a beneficially lower concentration of apo CIII in E2 carriers, a high proportion of plasma C16:0 was associated with insulin resistance in E4 carriers. Following FA intervention, a reduction in plasma long-chain n-3 PUFA was associated with a reduction in apo CII concentration in E2 carriers. Our novel data suggest that individuals with MetS may benefit from personalized dietary interventions based on APOE genotype.
dc.description.sponsorshipThe data used in this analysis was derived from the LIPGENE study, funded by the European Commission Framework Programme 6 (contract no. FOOD-CT-2003-505944) between 2004–2009.
dc.description.versionSi
dc.identifier.citationFallaize R, Carvalho-Wells AL, Tierney AC, Marin C, Kieć-Wilk B, Dembińska-Kieć A, et al. APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome. Sci Rep. 2017 Jul 24;7(1):6274
dc.identifier.doi10.1038/s41598-017-05802-2
dc.identifier.essn2045-2322
dc.identifier.pmcPMC5524844
dc.identifier.pmid28740125
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524844/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/s41598-017-05802-2.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11434
dc.issue.number1
dc.journal.titleScientific reports
dc.journal.titleabbreviationSci Rep
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.page.number10
dc.provenanceRealizada la curación de contenido 05/09/2024
dc.publisherNature Publishing Group
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectIDFOOD-CT-2003-505944
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-017-05802-2
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdult
dc.subjectAged
dc.subjectApolipoprotein C-II
dc.subjectApolipoprotein C-III
dc.subjectApolipoproteins E
dc.subjectDiet
dc.subject.decsGenotipo
dc.subject.decsLípidos
dc.subject.decsPolimorfismo genético
dc.subject.decsResistencia a la insulina
dc.subject.decsSíndrome metabólico
dc.subject.decsÁcidos grasos
dc.subject.meshFatty Acids
dc.subject.meshFemale
dc.subject.meshGenotype
dc.subject.meshHumans
dc.subject.meshInsulin Resistance
dc.subject.meshLipids
dc.subject.meshMale
dc.subject.meshMetabolic Syndrome
dc.subject.meshMiddle Aged
dc.subject.meshPolymorphism, Genetic
dc.titleAPOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number7
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
PMC5524844.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
Fallaize_APOE_MaterialSuplementario.doc
Size:
85 KB
Format:
Microsoft Word